Comparison of Acceleromyography (AMG) and Mechanomyography (MMG) for Establishing Potency of Neuromuscular Blocking Agents

Rigshospitalet

Status and phase: Completed; Phase 4

Conditions: Neuromuscular Blockade

Treatments: Device: TOF-Watch SX (Acceleromyography)

Study type: Interventional

Funder types: Other

Identifiers

NCT00660413

AMG-MMG D-R

Details and patient eligibility

About

The purpose of this study was to compare two methods for neuromuscular monitoring, acceleromyography and mechanomyography for establishing the dose-response relationship and the potency of a neuromuscular blocking agent using rocuronium as an example. We hypothesized that there would be no significant difference between potencies estimated using acceleromyography and mechanomyography.

Enrollment: 40 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ASA I-III
• Ideal weight +/-20%
• Both arms available for neuromuscular monitoring
• Surgery in supine position
• Participated surgery time more than 30 min

Exclusion criteria

• Pregnant and breast-feeding women
• Patients with known illness or use of medications known to influence the neuromuscular transmission
• Known significant renal or hepatic dysfunction
• Allergy to medications used in the study

Trial design

40 participants in 2 patient groups

AMG

Experimental group

Description:

Acceleromygraphy monitoring

Treatment:

Device: TOF-Watch SX (Acceleromyography)

MMG

Active Comparator group

Description:

Mechanomyography monitoring

Treatment:

Device: TOF-Watch SX (Acceleromyography)